Literature DB >> 27908881

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

Lauren Y Lee1, Daniela Hernandez1, Trivikram Rajkhowa1, Samuel C Smith1, Jayant Ranganathan Raman1, Bao Nguyen1, Donald Small1, Mark Levis1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27908881      PMCID： PMC5234222          DOI： 10.1182/blood-2016-10-745133

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  25 in total

1.  Antitumor activity of sorafenib in FLT3-driven leukemic cells.

Authors:  D Auclair; D Miller; V Yatsula; W Pickett; C Carter; Y Chang; X Zhang; D Wilkie; A Burd; H Shi; S Rocks; R Gedrich; L Abriola; H Vasavada; M Lynch; J Dumas; P A Trail; S M Wilhelm
Journal:  Leukemia       Date:  2007-01-04       Impact factor: 11.528

Review 2.  c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.

Authors:  S D Lyman; S E Jacobsen
Journal:  Blood       Date:  1998-02-15       Impact factor: 22.113

3.  Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.

Authors:  Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard Stone; Daniel Deangelo; Ilene Galinsky; Frank Giles; Elihu Estey; Hagop Kantarjian; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Journal:  Blood       Date:  2006-07-20       Impact factor: 22.113

4.  Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.

Authors:  Paolo Strati; Hagop Kantarjian; Farhad Ravandi; Aziz Nazha; Gautam Borthakur; Naval Daver; Tapan Kadia; Zeev Estrov; Guillermo Garcia-Manero; Marina Konopleva; Trivikram Rajkhowa; Menda Durand; Michael Andreeff; Mark Levis; Jorge Cortes
Journal:  Am J Hematol       Date:  2015-03-02       Impact factor: 10.047

5.  Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.

Authors:  Gautam Borthakur; Hagop Kantarjian; Farhad Ravandi; Weiguo Zhang; Marina Konopleva; John J Wright; Stefan Faderl; Srdan Verstovsek; Sheela Mathews; Michael Andreeff; Jorge E Cortes
Journal:  Haematologica       Date:  2010-10-15       Impact factor: 9.941

6.  Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Authors:  Il-Kyoo Park; Anjali Mishra; Jason Chandler; Susan P Whitman; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

7.  Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

Authors:  Ellen Weisberg; Christina Boulton; Louise M Kelly; Paul Manley; Doriano Fabbro; Thomas Meyer; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

Review 8.  FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Authors:  Michael R Grunwald; Mark J Levis
Journal:  Int J Hematol       Date:  2013-04-24       Impact factor: 2.490

9.  Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Authors:  B Douglas Smith; Mark Levis; Miloslav Beran; Francis Giles; Hagop Kantarjian; Karin Berg; Kathleen M Murphy; Tianna Dauses; Jeffrey Allebach; Donald Small
Journal:  Blood       Date:  2004-01-15       Impact factor: 22.113

10.  Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Authors:  Allison Galanis; Hayley Ma; Trivikram Rajkhowa; Abhijit Ramachandran; Donald Small; Jorge Cortes; Mark Levis
Journal:  Blood       Date:  2013-11-13       Impact factor: 22.113
View more
  86 in total

1.  Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

Authors:  Christine M McMahon; Jonathan Canaani; Bryan Rea; Rachel L Sargent; Julianne N Qualtieri; Christopher D Watt; Jennifer J D Morrissette; Martin Carroll; Alexander E Perl
Journal:  Blood Adv       Date:  2019-05-28

2.  Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?

Authors:  Sabine Kayser; Mark J Levis
Journal:  Int J Hematol Oncol       Date:  2017-02-24

Review 3.  Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia.

Authors:  Longzhen Cui; Yan Liu; Yifan Pang; Tingting Qian; Liang Quan; Zhiheng Cheng; Yifeng Dai; Xu Ye; Ying Pang; Jinlong Shi; Xiaoyan Ke; Depei Wu; Lin Fu
Journal:  Cancer Gene Ther       Date:  2019-07-11       Impact factor: 5.987

Review 4.  [Advances in targeted therapy for childhood acute myeloid leukemia].

Authors:  Ni-Na Wang; Qi-Dong Ye
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2017-07

Review 5.  Current and Future Molecular Targets for Acute Myeloid Leukemia Therapy.

Authors:  Shaheedul A Sami; Noureldien H E Darwish; Amanda N M Barile; Shaker A Mousa
Journal:  Curr Treat Options Oncol       Date:  2020-01-13

6.  Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Authors:  Jorge E Cortes; Martin S Tallman; Gary J Schiller; Denise Trone; Guy Gammon; Stuart L Goldberg; Alexander E Perl; Jean-Pierre Marie; Giovanni Martinelli; Hagop M Kantarjian; Mark J Levis
Journal:  Blood       Date:  2018-06-06       Impact factor: 22.113

7.  The growing landscape of FLT3 inhibition in AML.

Authors:  Catherine C Smith
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

8.  Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis.

Authors:  David J Young; Bao Nguyen; Ruiqi Zhu; Jaesung Seo; Li Li; Mark J Levis; Keith W Pratz; Amy S Duffield; Donald Small
Journal:  Blood Adv       Date:  2021-05-11

Review 9.  Emerging therapies for acute myeloid leukemia: translating biology into the clinic.

Authors:  Simon Kavanagh; Tracy Murphy; Arjun Law; Dana Yehudai; Jenny M Ho; Steve Chan; Aaron D Schimmer
Journal:  JCI Insight       Date:  2017-09-21

10.  Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.

Authors:  Taylor Bucy; John M Zoscak; Motomi Mori; Uma Borate
Journal:  Blood Adv       Date:  2019-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.